Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg
- Conditions
- Nonalcoholic Fatty Liver Disease
- Registration Number
- NCT04282447
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than hepato/gastroenterology and to examine risk factors associated with this condition. The prevalence of NASH will be investigated among 6 cohorts of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de Strasbourg.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- age ≥ 18 years
- outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.
- endocrinology cohort : type 2 diabetes patients
- infectious disease cohort : HIV positive patients
- rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis
- nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy or hypertensive nephropathy, including those receiving hemodialysis.
- cardiology cohorts: patients with history of angina, myocardial infarction, stroke or arteritis of lower limbs.
- internal medicine cohort: patients with auto immune systemic diseases such as lupus, sclerosis or rheumatoid arthritis.
- subjects who have given their informed consent
- Subjects affiliated to a social security system
Exclusion Criteria
- alcohol consumption > 30g/d in male or > 20g/d in female in the past 6 months
- history of chronic viral hepatitis
- history of liver auto immune disease, genetic hemochromatosis, Wilson disease
- biliary disease, bile duct obstruction
- drug-induced liver injury
- secondary liver cancer or other active cancer
- organ graft
- use of medications associated with secondary NAFLD (corticosteroids, tamoxifen, amiodarone, methotrexate).
- congestive heart failure
- AIDS
- pregnancy, breastfeeding
- no information could be given to the patient (subject faces emergency situation, comprehension difficulties, etc.)
- patient under guardianship
- patients under judicial protection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estimated prevalence of NASH with advanced fibrosis among several hospital specialty clinics 3 months To assess the estimated prevalence of NASH , calcul of the FIB4
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Les Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France